Final analysis results from TITAN: A phase 3 study of apalutamide (APA) vs placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving adrogen deprivation therapy (ADT)

Final analysis results from TITAN: A phase 3 study of apalutamide (APA) vs placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving adrogen deprivation therapy (ADT) Meeting Abstract

publication date

September 1, 2021

webpage

Web of Science

published in

ONCOLOGY RESEARCH AND TREATMENT Journal

start page

74

end page

74

volume

44